Yajing Feng

Yajing Feng

Auto-generated profile, based on publicly available information

Yajing Feng

Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YFYajing Feng
Yajing Feng
FDFujiao Duan
Fujiao Duan
CSChunhua Song
Chunhua Song
XZXia Zhao
Xia Zhao
LDLiping Dai
Liping Dai
SCShuli Cui
Shuli Cui
Systematic evaluation of cancer risk associated with rs2292832 in miR‑149 and rs895819 in miR‑27a: a comprehensive and updated meta‑analysis

6 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YFYajing Feng
Yajing Feng
FDFujiao Duan
Fujiao Duan
WLWeigang Liu
Weigang Liu
XFXiaoli Fu
Xiaoli Fu
SCShuli Cui
Shuli Cui
ZYZhenxing Yang
Zhenxing Yang
Prognostic value of the microRNA-214 in multiple human cancers: a meta-analysis of observational studies Prognostic value of the microRNA-214 in multiple human cancers: a meta-analysis of observational studies

26 August 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YFYajing Feng
Yajing Feng
JCJunhui Chai
Junhui Chai
JZJichun Zhu
Jichun Zhu
YZYuehua Zhang
Yuehua Zhang
KWKaijuan Wang
Kaijuan Wang
FDFujiao Duan
Fujiao Duan
Objective To estimate mortality trends and disease burden of Digestive system cancer (DSC) in China during 2006–2020, using demographic and mortality data from cause-of-death surveillance dataset of China. Methods Joinpoint regression was applied to calculate the crude mortality rate (CMR), age standardized mortality rate (ASMR), annual percentage change (APC), and average annual percentage change (AAPC) for analyzing the trend of death change, and years of life expectancy lost (LLE) and early death lost life (YLL) were utilized to assess disease burden. Bayesian Age-Period-Cohort models were employed to project future mortality trends up to 2045. Results From 2006 to 2020, the combined ASMR and YLL rates for female DSC showed stability, with an average life expectancy loss of 7.06 years and the highest YLL rate in the 60–65 age group. Esophageal cancer, gastric cancer, and liver cancer showed a decreasing trend from 2015 to 2020, with APCs of -4.59% (P = 0.001), -5.25% (P = 0.002), and − 3.74% (P = 0.002), respectively. Colorectal cancer and pancreatic cancer showed an upward trend in 2016–2020, with APC of 1.85% (P = 0.021) and 2.74% (P = 0.023), respectively. The trend of standardized YLL rate changes was statistically significant (AAPC = − 2.8%, 95% CI: − 3.3%, 2.3%). The standardized YLL rates of esophageal cancer (AAPC=-5.0%, 95% CI: -5.6%, 4.5%), gastric cancer (AAPC = − 4.2%, 95% CI: − 4.8%, 3.7%), and liver cancer (AAPC = − 2.7%, 95% CI: − 3.3%, 2.2%) all showed a downward trend. By 2045, a significant downward trend in both death counts and ASMRs of DSC in China from 2006 to 2045 across all genders (Ptrend<0.001), with the most pronounced decline observed in males. Conclusions These findings reveal divergent trends in the distribution of DSC in China. Implementing gender-specific strategies, particularly for males, and strengthening cancer surveillance systems are crucial for sustained public health improvements.

17 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YFYajing Feng
Yajing Feng
MYMengmeng Yin
Mengmeng Yin
JCJunhui Chai
Junhui Chai
JZJicun Zhu
Jicun Zhu
YZYuehua Zhang
Yuehua Zhang
FDFujiao Duan
Fujiao Duan
Objective: This study aimed to systematically assess the predictive value of microsatellite instability (MSI) combined with programmed death-ligand 1 (PD-L1) expression for prognosis and immunotherapy response in patients with gastric cancer (GC). Methods: An individual patient data (IPD) meta-analysis was performed in accordance with the PICOS framework and PRISMA 2020 guidelines. A comprehensive literature search was performed across English and Chinese databases to identify cohort studies or randomized controlled trials (RCTs) that simultaneously evaluated MSI status and PD-L1 expression, and reported overall survival (OS), disease-free survival (DFS) with 95% confidence intervals (CIs) were used as pooled effect measures. Fixed-effect or random-effects models were applied based on heterogeneity assessed by the I ² statistic. Subgroup analyses were stratified by ethnicity, pathological stage, Lauren classification, chemotherapy timing, MSI detection platform, and PD-L1 antibody clone. The interactive effect of MSI-H and PD-L1 expression was evaluated using radar plots. Results: Nine studies involving 6,667 GC patients were included. For OS, MSI-H alone (HR = 0.500, 95%CI: 0.357-0.700, P < 0.001), and MSI-H/MSI-L combined (HR = 0.641, 95%CI: 0.437-0.939, P = 0.025) were associated with better outcomes than MSS; PD-L1 positivity predicted poorer OS (HR = 1.517, 95%CI: 1.077-2.137, P = 0.017); MSI-H+PD-L1 negative patients had the most favorable OS (HR = 0.380, 95%CI: 0.255-0.566, P < 0.001), while MSI-H+PD-L1 positive patients had poorer OS than MSS+PD-L1 negative patients (HR = 2.076, 95%CI: 1.238-3.479, P = 0.006). For DFS, MSI-H alone (HR = 0.506, 95%CI: 0.360-0.710, P < 0.001) and MSI-H/MSI-L combined (HR = 0.530, 95%CI: 0.402-0.698, P < 0.001) outperformed MSS, but PD-L1 expression showed no significant DFS association (HR = 1.189, 95%CI: 0.472-2.998, P = 0.709). Subgroup analyses identified TNM stage, Lauren classification, chemotherapy timing, and MSI detection method as significant effect modifiers (all interaction P < 0.05). Pooled immunotherapy data showed that MSI-H patients had higher ORR than MSS (OR = 3.580, P < 0.001), and MSI-H+PD-L1 positive patients achieved the highest response rates (OR = 4.100 vs. MSI-H+PD-L1 negative, P < 0.001). Sensitivity analysis confirmed result stability, and publication bias was minimal. Conclusion: MSI-H status is a robust favorable prognostic factor for GC, while PD-L1 positivity indicates adverse OS prognosis. The combination of MSI and PD-L1 expression enables refined prognostic stratification of GC patients.